Human rituximab and hyaluronidase have authorization for usage alone or in combination with other medicines to treat:
- Adults with chronic lymphocytic leukemia (CLL) – It’s in use with cyclophosphamide and fludarabine phosphate.
- Diffuse large B-cell lymphoma – is a kind of lymphoma that affects many people. It’s in use with anthracycline chemotherapy in individuals who haven’t had their illness treated yet.
- Follicular lymphoma – is a kind of lymphoma that affects the follicles. In adults with follicular lymphoma:
- Has relapsed or is resistant to therapy (does not respond to treatment).
- Is not under treatment in any way.
- Has shown a positive response to rituximab in combination with chemotherapy.
- After chemotherapy, cancer has not advanced.
Rituximab and hyaluronidase human is a subcutaneously administered version of rituximab. This typically takes less time to administer than rituximab, which is an infusion. Only after patients have received one complete dose of rituximab via infusion is the subcutaneous form utilized. See the Drug Information Summary for Rituximab for further information about rituximab that may pertain to rituximab and hyaluronidase humans.
Detailed scientific definition – Definition from the NCI Drug Dictionary –
Rituximab and Hyaluronidase Human – MedlinePlus Information A summary of key facts regarding this medication in layman’s terms, which may contain the following:
cautions about this medicine, what it’s in use for and how to use it, what you should tell your doctor before taking it, what you should know about it before using it, other drugs that might interact with it, and possible negative effects
Drugs are frequently under investigation to see whether they can assist treat or prevent conditions other than those for which they have authorization. Only authorized uses of the medication come under this patient information leaflet. Much of the material, however, may also apply to unapproved uses that are under investigation.